Please assess the completion status of the following clinical trial:

Trial Title: Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Self-report of ≥3 episodes of emesis occurring in a cyclic pattern for greater than 1 month in the preceding 2 years~3. Current episode \>2 hours of emesis~4. At least one episode of emesis/forceful retching witnessed (including products of emesis at bedside) or heard by an independent observer (healthcare provider or family/friend) in the emergency department~5. Self-reported frequent (near daily to daily x at least 6 months) use of cannabis by inhalation.~6. Working diagnosis of cannabis hyperemesis syndrome in the opinion of the treating emergency physician~Exclusion Criteria:~1. Chronic, daily use of opioid equivalent to ≥10mg morphine/day~2. Inability to comprehend study consent or instructions~3. Unreliable follow-up/unlikely to return for cross-over~4. Administration of an intravenous antiemetic, anticholinergic or antipsychotic (other than up to 100mg dimenhydrinate) in the previous 24 hours~5. Allergy or intolerance to haloperidol or ondansetron~6. Pregnancy~7. Any other medical or psychiatric condition that in the opinion of the enrolling physician would interfere with participation in the trial~8. Current active participation in an investigational drug trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Ondansetron 8mg (Type: ACTIVE_COMPARATOR): 8mg Ondansetron prepared in a 100mL normal saline mini-bag
- Haloperidol 0.05mg/kg (Type: EXPERIMENTAL): 0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
- Haloperidol 0.1mg/kg (Type: EXPERIMENTAL): 0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag

Based on this trial design, predict the completion outcome and termination type (if applicable).